![]() ![]() ![]() The primary series of the Novavax COVID-19 Vaccine, Adjuvanted is two doses (0.5 mL each) given 3 weeks apart. The Novavax COVID-19 Vaccine, Adjuvanted is authorized for emergency use to provide a two-dose primary series to individuals 12 years of age and older. The Novavax COVID-19 Vaccine, Adjuvanted is a suspension for intramuscular injection. See “ MANDATORY REQUIREMENTS FOR THE NOVAVAX COVID-19 VACCINE, ADJUVANTED ADMINISTRATION UNDER EMERGENCY USE AUTHORIZATION” for reporting requirements. Vaccination providers enrolled in the federal COVID-19 Vaccination Program must report all vaccine administration errors, all serious adverse events, cases of myocarditis, cases of pericarditis, cases of Multisystem Inflammatory Syndrome (MIS) in adults and children, and cases of COVID-19 that result in hospitalization or death following administration of the Novavax COVID-19 Vaccine, Adjuvanted. SUMMARY OF INSTRUCTIONS FOR COVID-19 VACCINATION PROVIDERS Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product, Novavax COVID-19 Vaccine, Adjuvanted, for active immunization to prevent COVID-19 in individuals 12 years of age and older. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |